New genital herpes vaccine candidate provides powerful protection in preclinical tests

New genital herpes vaccine candidate provides powerful protection in preclinical tests

Approximately 500 million people around the world are infected with the genital herpes virus known as herpes simplex virus 2 (HSV2). A vaccine that could bring an end to this global pandemic is needed desperately, yet no candidate vaccine has ever performed well in clinical trials. Now scientists have shown that a new type of vaccine provides powerful protection in standard guinea pig and monkey models of HSV2 infection.

7
Like
Save

Comments

Comments are disabled for this post.